ARTICLE | Emerging Company Profile

Veracyte: Benign Afirma-tion

Veracyte's molecular diagnostic could reduce unnecessary thyroid surgeries

December 6, 2010 8:00 AM UTC

Up to 70,000 patients have unnecessary thyroidectomies in the U.S. annually because of inconclusive results using current cytopathology techniques. In hopes of reducing needless surgeries, Veracyte Inc. is developing Afirma, a non-invasive molecular diagnostic to identify benign thyroid nodules from inconclusive biopsies.

Veracyte was founded in 2008 with the goal of identifying clinically unmet needs in the cytopathology space where molecular diagnostics could make a difference, according to CEO Bonnie Anderson...